List of Studies ( Metabolite:GlcCer 18:2;O2/20:0)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006911 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004058 | AN006709 | Targeted Lipid and Metabolite Profiling in ATP13A2 knockout (KO) in HAP1 cells | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
| ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | LC-MS |
